# SPECIAL 510(k): Device Modification OIR Decision Summary

RE: DOCUMENT NUMBER K150375

This 510(k) submission contains information/data on modifications made to the SUBMITTER’S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable:

1. The name and 510(k) number of the SUBMITTER’S previously cleared device. LIAISON® VZV IgG and LIAISON® Control VZV IgG 510(k) number: K061820

2. Submitter’s statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED. There are changes in labeling which are described below.

3. A description of the device MODIFICATION(S), in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed.

The changes were for:

A. Changes to the LIAISON VZV IgG: 1. Increase in number of tests per kit from 50 to 100 tests. 2. Extension of On-Board and Open Use stability claim for the Reagent Integral from four weeks to eight weeks when stored at ${ 2 } { - } 8 ^ { \circ } \mathsf { C }$ in a refrigerator or on board the analyzer. 3. Calibration stability extension from two weeks to eight weeks. 4. Extend refrigerated storage $( 2 { - } 8 ^ { \circ } \mathsf { C } )$ for specimens from two days to seven days. 5. Addition of specimen stability claim that allows samples to undergo five freeze-thaw cycles. 6. Changes to the Quality Control recommendations to reflect the change in the matrix composition of the LIAISON® Control VZV IgG.

B. Changes to the LIAISON® Control VZV IgG:

1. Controls (Positive and Negative) to be provided in a serum based matrix ( $100 \%$ human serum).   
2. Extension of On-Board and Open Use stability claim for controls from four weeks to eight weeks when stored at ${ 2 } { - } 8 ^ { \circ } \mathsf { C }$ .   
3. Addition of a description of Assigned Values of the controls and the procedure for using the controls.

# 4. Comparison Information

<table><tr><td colspan="3" rowspan="1">Similarities LIAISON®vZV IgG</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Predicate DeviceVZV IgG K061820,cleared 02/26/2007</td><td colspan="1" rowspan="1">Modified DeviceDiaSorin LIAISON® VZV IgG</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications forUse</td><td colspan="1" rowspan="1">The DiaSorin LIAISON® VZV IgG useschemiluminescence immunoassay (CLIA)tchnology on the LIAISO® Analyzer familyfor the qualitative detection of specific IgGantibodies to varicella-zoster virus (VZV) inhuman serum. This assay can be used as anaid in the determination of previous infection ofvaricella-zoster virus.The assay performance in detectingantibodies to VZV in individuals vaccinatedwith the FDA- licensed VZV vaccine isunknown. The user of this assay isresponsible for establishing the performancecharacteristics with VZV vaccinatedindividuals.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Technology/Assay Principle</td><td colspan="1" rowspan="1">Chemiluminescent Immunoassay (CLIA)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">SampleHandling/AssayProcessing</td><td colspan="1" rowspan="1">Automated</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent IntegralConfiguration(1 compartmenteach reagent)</td><td colspan="1" rowspan="1">•       Magnetic particlesCalibrator 1••       Calibrator 2•        Specimen Diluent•       Conjugate</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Raw Materials</td><td colspan="1" rowspan="1">No Change•      Antigen: Inactivated varicella-zostervirus lysate (ROD strain)Detector: Mouse monoclonal anti-human IgG conjugated to isoluminolderivative•       Capture: Magnetic microparticlescoated with varicella-zoster antigen</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">ReagentFormulation</td><td colspan="1" rowspan="1">No Change</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">ManufacturingProcess</td><td colspan="1" rowspan="1">No Change</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">Store at 2-8°C until ready to use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Similarities LIAISON® VZV IgG</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Predicate DeviceDiaSorin LIAISON®VZV IgG K061820,cleared 02/26/2007</td><td colspan="1" rowspan="1">Modified DeviceDiaSorin LIAISON® vZV IgG</td></tr><tr><td colspan="1" rowspan="1">MeasuredAnalyte</td><td colspan="1" rowspan="1">IgG antibodies to Varicella-zoster virus</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Human Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">20 uL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">AssayProcedure</td><td colspan="1" rowspan="1">•       Dispense calibrators, controls, orsamplesDispense magnetic particlesDispense specimen diluent•       IncubateWash•Dispense conjugateIncubate•WashDispense starter reagentMeasure Light emitted (RLUs)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Total IncubationTime</td><td colspan="1" rowspan="1">21 minutes</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">MeasurementSystem</td><td colspan="1" rowspan="1">Photomultiplier (flash chemiluminescencereader</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Two point verification of stored master curve</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Unit of Measure</td><td colspan="1" rowspan="1">Index Value</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Cut-Off</td><td colspan="1" rowspan="1">150 Index Value</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Equivocal Zone</td><td colspan="1" rowspan="1">135 - 165 Index Value</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Included with kit</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">AssayPerformanceCharacteristics</td><td colspan="1" rowspan="1">No Change</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Provided Separately</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences LIAISON® VZV IgG</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Predicate DeviceDiaSorin LIAISON®VZV IgG K061820,cleared 02/26/2007</td><td colspan="1" rowspan="1">Modified DeviceDiaSorin LIAISON® VZV IgG</td></tr><tr><td colspan="1" rowspan="1">Tests per Kit</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="1">ReagentVolume</td><td colspan="1" rowspan="1">Magnetic particles (1.3ml)Conjugate (13ml)</td><td colspan="1" rowspan="1">Magnetic particles (2.5 ml)Conjugate (23ml)</td></tr><tr><td colspan="1" rowspan="1">Open Use/OnBoard Stability</td><td colspan="1" rowspan="1">Four (4) weeks at 2-8°C or on boardthe analyzer</td><td colspan="1" rowspan="1">Eight (8) weeks at 2-8°C or onboardthe analyzer</td></tr><tr><td colspan="1" rowspan="1">CalibrationStability</td><td colspan="1" rowspan="1">Fourteen (14) days</td><td colspan="1" rowspan="1">Eight (8) weeks</td></tr><tr><td colspan="1" rowspan="1">Serum Storageat</td><td colspan="1" rowspan="1">Two (2) days</td><td colspan="1" rowspan="1">Seven (7) days</td></tr><tr><td colspan="1" rowspan="1">Serum StorageFreeze-ThawCycles</td><td colspan="1" rowspan="1">Samples should not be repeatedlyfrozen and thawed.</td><td colspan="1" rowspan="1">Samples are stable through five (5)freeze-thaw cycles.</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Similarities LIAISON® Control VZV IgG</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Predicate DeviceDiaSorin LIAISON® VZV IgG K061820,cleared 02/26/2007</td><td colspan="1" rowspan="1">Modified DeviceDiaSorin LIAISON® vZV IgG</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The LIAISON® VZV IgG controls(negative, positive controls) are usedfor monitoring substantial reagentfailure of the LIAISON® VZV IgGchemiluminescent immunoassay(CLIA). The LIAISON®VZV IgGquality control material contains a 5%serum matrix and may not adequatelycontrol the DiaSorin LIAISON® VZVIgG assay for serum specimens. Theperformance of the LIAISON® VZVIgG controls has not been establishedwith any other VZV assay orinstrument platforms different fromLIAISON® and LIAISON® XL.</td><td colspan="1" rowspan="1">The DiaSorin LIAISON® ControlVZV IgG (negative and positive) isintended for use as assayedquality control samples to monitorthe performance of the DiaSorinLIAISON® VZV IgG assay on theLIAISON® Analyzer family. Theperformance characteristics of theLIAISON® VZV Control IgG havenot been established for any otherassay or instrument platformsdifferent from LIAISON®andLIAISON® XL.</td></tr><tr><td colspan="1" rowspan="1">ReagentConfiguration</td><td colspan="1" rowspan="1">2 vials each level (negative andpositive) 0.7 mL/vial, ready to use.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">Store at 2-8° C until ready to use.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences LIAISON® Control VZV IgG</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Predicate DeviceDiaSorin LIAISON® VZV IgGK061820, cleared 02/26/2007</td><td colspan="1" rowspan="1">Modified DeviceDiaSorin LIAISON® VZV IgG</td></tr><tr><td colspan="1" rowspan="1">NegativeControl</td><td colspan="1" rowspan="1">5% Human Serum non-reactive for VZVIgG antibodies, stabilized in TRIS-NaCIbuffer, preservatives.</td><td colspan="1" rowspan="1">Human Serum non-reactive forVZV IgG antibodies, 0.2% ProClin.</td></tr><tr><td colspan="1" rowspan="1">Positive Control</td><td colspan="1" rowspan="1">5% Human Serum/plasma reactive forVZV IgG antibodies, stabilized in TRIS-NaCl buffer, preservatives, inert yellowdye.</td><td colspan="1" rowspan="1">Human Serum reactive for VZV IgGantibodies, 0.2% ProClin.</td></tr><tr><td colspan="1" rowspan="1">Open UseStability</td><td colspan="1" rowspan="1">Once opened controls are stable for four(4) weeks when properly stored at 2-8°Cbetween uses.</td><td colspan="1" rowspan="1">Once opened controls are stable foreight (8) weeks when properly storedat 2-8°C between uses.</td></tr></table>

# 5. A Design Control Activities Summary which includes:

a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis.

b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied. Stability studies on reagents, calibrators, controls and serum were carried out. Precision and matrix effect studies were also performed.

c) A “Declaration of Conformity” statement was also submitted for the manufacturing facility and validation activities and signed by the Quality Assurance and Regulatory Affairs Manager, Italy. The statements indicate that:

I. The manufacturing facility is in conformance with design control procedure requirements as specified in 21 CFR 820.30 and the records are available for review.   
II. The validation activities, as required by the risk analysis, for the modification were performed by the designated individuals and the results demonstrated that the predetermined acceptance criteria were met.

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter’s description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.